Theramex Announces an Agreement with Enzene Biosciences Limited for the Development and Commercialisation of Tocilizumab, a Biosimilar for the Treatment of Rheumatoid Arthritis
23.12.2021 17:06:00 EET | Business Wire | Press release
Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, has entered into an agreement with Enzene Biosciences Limited to develop, register and commercialise a biosimilar drug of Roche’s reference medicine RoActemra® (Tocilizumab). Tocilizumab, in combination with Methotrexate (MTX), is indicated for the treatment of rheumatoid arthritis. It is planned to be commercialised from 2026 in Europe, the UK, Switzerland, and Australia.
Theramex’s Tocilizumab product will be available in parenteral vials, subcutaneous prefilled syringes and autoinjectors. The reference product RoActemra® is indicated for the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with methotrexate; moderate to severe RA adult patients who have not responded well/intolerant to DMARDs or Anti-TNFs; active systemic juvenile idiopathic arthritis in patients 1 year of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids; juvenile idiopathic polyarthritis in patients 2 years of age and older unresponsive to MTX; treatment of Giant Cell Arteritis in adults; and chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older.
Rheumatoid arthritis is a chronic condition that causes pain, swelling and stiffness in the joints. The condition usually affects the hands, feet and wrists. There may be periods where symptoms become worse, known as flares. A flare can be difficult to predict, but with treatment it's possible to decrease the number of flares and minimise or prevent long-term damage to the joints. Some people with rheumatoid arthritis also experience problems in other parts of the body, or more general symptoms such as tiredness and weight loss1.
“Rheumatoid arthritis affects more women than men, so the addition of this biosimilar drug to our existing Rheumatology portfolio continues our strategic determination to improve access and affordability of important treatments for women. We are excited to expand our focus in Rheumatology to now include rheumatoid arthritis to help even more patients with bone diseases and joint pain”, said Theramex CEO Robert Stewart .
Dr. Himanshu Gadgil, Enzene's Whole Time Director said, "The development of Enzene’s Tocilizumab, through our innovative efforts in the manufacturing of monoclonal antibodies, marks another highlight in a series of endeavours driven by our mission to provide affordable and expanded access to crucial medicines. Our partnership with Theramex bolsters our mission to bring affordable healthcare to patients across the world”.
About Theramex
Theramex is a leading global speciality pharmaceutical company dedicated to women and their health. We support women at every stage of their lives by providing a broad portfolio of innovative and established brands covering contraception, fertility, menopause and osteoporosis. Our commitment is to listen to and understand our patients, serve their needs and offer healthcare solutions to help improve their lives. Our vision is to be a lifetime partner for women and the healthcare professionals who treat them by providing patient-focused and effective solutions that care for and support women through every stage of life.
About Enzene Biosciences Ltd.
Enzene is an innovation-driven biotech company, a subsidiary of Alkem Laboratories Ltd. (One of the top five pharmaceutical companies in India*) located in Pune, India. Enzene's focus lies in producing biosimilars, novel biologics, synthetic peptides and phytopharmaceuticals. Enzene also offers a range of biologics CDMO and CMO services.
(*as per the latest IQVIA data of MAT July 2021)
For more information on Enzene Biosciences Ltd., please visit www.enzene.com
For more information on Alkem Laboratories Ltd., please visit www.alkemlabs.com
1 https://www.nhs.uk/conditions/rheumatoid-arthritis/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211223005258/en/
Contact information
Theramex
Jesús López | Associate Director, Communication & Digital | Jesus.Lopez@Theramex.com
Enzene Biosciences Ltd.
For media enquiries,
Dr. Tarun Chawla
Head - Business Development & Business Operations
Enzene Biosciences Ltd.
For any further enquiries, please reach out to: bd@enzene.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Secures Significant U.S. Army LOCODA Radio Order Following Rapid Development Push23.6.2026 20:42:00 EEST | Press release
Delivering capability at mission speed, Thales subsidiary, Thales Defense & Security, Inc. (TDSI), has secured an order for up to 5,000 Low Cost Data Architecture (LOCODA) Radio Adaptable Transport (RAT) platforms. The Thales RAT solution, which was conceived, developed and field-ready less than four months, modernizes voice and data communications and integrates effortlessly into radio mounts across all current and future U.S. Army vehicle platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623043996/en/ Thales Radio Adaptable Transport (c)Thales The LOCODA RAT platform provides soldiers with a reliable, adaptable communications capability they can depend on across any mission and environment. By reusing existing vehicle radio mounts and supporting a wide range of radios and mission modules, it reduces setup time and simplifies integration in the field. Soldiers gain secure, flexible voice and data connectivity tha
Epicor Prism Launches Across European Markets, Bringing Embedded, Industry-Specific AI to Manufacturers23.6.2026 18:55:00 EEST | Press release
Epicor has expanded its AI-driven ERP strategy in the UK and select European markets with the general availability of Epicor Prism, a portfolio of vertical AI agents designed specifically for the supply chain industries. Embedded directly in Epicor Kinetic, Epicor Prism gives customers conversational access to live ERP data and related documents without needing specialised analytics skills or separate AI tools. The launch reflects a broader shift in ERP from systems of record to systems of outcomes that help users interpret data, make decisions and take action in real time — a transformation Epicor calls Cognitive ERP. Responding to pressure on productivity and skills European manufacturers are under growing pressure to raise productivity, strengthen supply chain resilience and remain globally competitive despite workforce constraints and ongoing digital skills shortages. While many organisations continue to invest heavily in ERP, turning operational data into timely insight at the poi
Airship Appoints Laura Zwahlen as Chief Revenue Officer23.6.2026 18:00:00 EEST | Press release
Airship, the mobile-first customer experience company, today announced the appointment of Laura Zwahlen as Chief Revenue Officer (CRO). Zwahlen will oversee all global revenue-generating activities, driving the alignment, execution, and strategy across Airship’s sales, account management, and customer success teams to accelerate the company’s market leadership and customer impact. She will report directly to CEO Brett Caine. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623145620/en/ Laura Zwahlen, Chief Revenue Officer (CRO) of Airship Zwahlen brings more than 20 years of go-to-market and revenue leadership experience, with a proven track record of guiding technology organizations through rapid growth, strategic acquisitions, and public offerings. Previously, she served as CRO at NextRoll (the parent company of AdRoll and AdRoll ABM) where she led global revenue teams and drove initiatives centered on sustainable growth
INRIX Data Reveals How the 2026 FIFA World Cup Is Reshaping Traffic Across 11 U.S. Cities23.6.2026 17:56:00 EEST | Press release
INRIX, a global leader in transportation data and analytics, today announced the launch of its 2026 FIFA World Cup Data Hub, providing transportation agencies, event organizers, media, and travelers with a comprehensive, real-time view of how the world’s largest sporting event is moving millions of people. The 2026 FIFA World Cup spans 16 cities across the United States, Canada, and Mexico, making it the most geographically diverse World Cup in history. With matches across 11 U.S. stadiums attracting millions of fans from around the world, transportation demands vary as widely as the cities themselves. INRIX is uniquely positioned to capture that complexity at scale with unprecedented speed, backed by a data infrastructure no other company can beat. Drawing on more than 300 million connected vehicles and devices, a 50-petabyte transportation data lake, and 44 billion data points generated daily, INRIX can analyze traffic conditions around any U.S. stadium within hours of a match. The c
IQM achieves milestone in quantum error correction, enabling fault-tolerant computing in the near-term23.6.2026 17:41:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced a significant achievement in quantum error correction, using directional tile codes, marking a major step toward practical, large-scale fault-tolerant quantum computing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623243333/en/ IQM achieves milestone in quantum error correction, enabling fault-tolerant computing in the near-term The research, available on arXiv, and co-authored by IQM researchers and collaborators at Freie Universität Berlin, the University of Edinburgh, and Johannes Gutenberg-Universität Mainz, introduces ‘directional tile codes’, a new family of quantum error-correcting codes that resolves one of the central tensions in quantum computing. As IQM prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ), this research advances a core pillar of its technology ro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom